

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2024

(Rs. in Lakhs)

	Particulars	3 months ended 30.09.2024	Preceeding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	100005	81100	95338	181105	169140	340725
2	Other income	3219	3585	2847	6804	6527	12348
3	Total Income (1+2)	103224	84685	98185	187909	175667	353073
	Expenses						
	(a) Cost of materials consumed	13725	13333	7971	27058	22518	50499
	(b) Purchases of stock-in-trade	21674	17274	26062	38948	43482	85308
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	2262	(1326)	971	936	(3467)	(6964)
	(d) Employee benefits expense	15071	15128	14521	30199	31021	62439
	(e) Finance costs	27	37	43	64	71	180
	(f) Depreciation and amortisation expense	1686	1641	1811	3327	3447	6968
	(g) Other expenses	15378	13749	17155	29127	32803	59378
4	Total expenses	69823	59836	68534	129659	129875	257808
5	Profit before exceptional items and tax (3-4)	33401	24849	29651	58250	45792	95265
6	Exceptional items [credit/(charge)] (Refer Note 2)	469	-	-	469	1730	(14361)
7	Profit before tax (5+6)	33870	24849	29651	58719	47522	80904
8	Tax expense						
	(a) Current tax	9746	6333	9060	16079	14323	23571
	(b) Deferred tax	(745)	351	(963)	(394)	(1413)	(1136)
9	Profit for the period/year (7-8)	24869	18165	21554	43034	34612	58469

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2024

(Rs. in Lakhs)

	Particulars	3 months ended 30.09.2024	Preceeding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
10	Other comprehensive income							
	(i) Items that will not be reclassified to profit or loss	-	-	-	-		(557)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-		140	
11	Total comprehensive income for the period (9+10)	24869	18165	21554	43034	34612	58052	
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941	
	Other equity						161468	
	Earnings per share (EPS) (of Rs. 10 each)							
	Basic and diluted EPS before Exceptional items (Rs.)	14.45	10.72	12.72	25.17	19.66	40.83	
	Basic and diluted EPS after Exceptional items (Rs.)	14.68	10.72	12.72	25.40	20.43	34.51	
		Not Annualised						

Statement of Assets and Liabilities		Standalone (Rs. in Lakhs)	
		As at 30.09.2024	As at 31.03.2024
Particulars		Unaudited	Audited
A	ASSETS		
1	<u>Non-Current Assets</u>		
	(a) Property, Plant and Equipment	26286	27936
	(b) Right of use Assets	1387	1744
	(c) Capital work-in-progress	2091	1393
	(d) Investment Property	83	90
	(e) Intangible assets	1834	2355
	(f) Financial Assets		
	i. Investments	2449	2449
	ii. Loans	400	1100
	iii. Other financial assets	1098	1019
	(g) Current tax assets (net)	19281	20846
	(h) Deferred tax assets (net)	14989	14595
	(i) Other non-current assets	5230	4668
	Total non-current assets	75128	78195
2	<u>Current assets</u>		
	(a) Inventories	50047	51430
	(b) Financial assets		
	(i) Current Investments	100082	81322
	(ii) Trade receivables	26836	22206
	(iii) Cash and cash equivalents	3849	6215
	(iv) Bank balances other than (iii) above	106075	99905
	(v) Other financial assets	7308	11150
	(c) Other current assets	3684	4357
	Total current assets	297881	276585
	Total Assets	373009	354780

Statement of Assets and Liabilities		Standalone (Rs. in Lakhs)	
		As at 30.09.2024	As at 31.03.2024
Particulars		Unaudited	Audited
B	EQUITY AND LIABILITIES		
	<u>Equity</u>		
	(a) Equity Share Capital	16941	16941
	(b) Other Equity	150525	161468
	Total equity	167466	178409
	<u>Liabilities</u>		
1	<u>Non-current liabilities</u>		
	(a) Financial Liabilities		
	i. Lease liabilities	418	647
	ii. Other financial liabilities	2	8
	(b) Provisions	25466	24621
	Total non-current liabilities	25886	25276
2	<u>Current liabilities</u>		
	(a) Financial Liabilities		
	i. Lease liabilities	1061	1220
	ii. Trade payables		
	Due to Micro Enterprises and Small Enterprises	738	193
	Due to others	60665	61132
	iii. Other financial liabilities	17559	14211
	(b) Other current liabilities	5864	5129
	(c) Provisions	39861	39352
	(d) Current tax liabilities (net)	53909	29858
	Total current liabilities	179657	151095
	Total liabilities	205543	176371
	Total equity and liabilities	373009	354780

Condensed Statement of Cash Flow		Standalone (Rs. in Lakhs)	
	Particulars	Period ended	Period ended
		September 30, 2024	September 30, 2023
		Unaudited	Unaudited
A.	<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>		
	Profit before exceptional items and tax from : Continuing operations	58250	45792
	Operating Profit before working capital changes	55270	43341
	Net cash generated from operating activities	71247	32671
B.	<u>CASH FLOWS USED IN/FROM INVESTING ACTIVITIES</u>	(18279)	25139
C.	<u>CASH FLOWS USED IN FINANCING ACTIVITIES</u>	(55334)	(54975)
	<u>Net (decrease) /increase in cash and cash equivalents</u>	(2366)	2835
	Cash and cash equivalents at the beginning of the financial year	6215	2974
	Cash and cash equivalents at the end of the period	3849	5809
	<u>Net (decrease) /increase in cash and cash equivalents</u>	(2366)	2835

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th October 2024. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter and six months ended 30th September 2024.
- Exceptional items pertaining to prior period / year :
 - Exceptional items credit for the quarter and half year ended 30th September 2024 of Rs.469 lakhs and for the half year ended 30th September 2023 of Rs. 1730 lakhs is on account of profit on sale of surplus residential properties.
 - Exceptional items charge for the year ended 31st March 2024 of Rs.14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
- During the quarter ended September 30, 2024, the Company has received an income tax order issuing refund of Rs. 222,32 lakhs (including interest) for Assessment Year 2022-23.
- The Board of Directors at their meeting held on 29th October 2024 declared a special interim dividend of Rs. 12 per equity share of face value of Rs. 10 each.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

29th October, 2024

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

